Relative Bioavailability Study of GSK1265744 Formulations
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods)
in healthy adult subjects. During each period, subjects will receive a single dose of
GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours (8
days) and safety assessments will be performed. Each period will be separated by a washout
period of at least 14 days and a follow-up visit will occur 10 to 14 days after the last dose
of study drug.